All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

FDA accepts a Biologics License Application for obe-cel in patients with R/R B-ALL

Jan 25, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

Bookmark this article

On January 22, 2024, the U.S. Food and Drug Administration (FDA) accepted a Biologics License Application for obecabtagene autoleucel (obe-cel), a novel autologous CD19 CAR T-cell therapy designed with a fast off-rate CD19 binding domain to improve persistence and reduce toxicities, for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. This decision was based on data from the pivotal phase II FELIX study (NCT04404660).1,2

The ALL hub previously reported the efficacy and safety outcomes from the FELIX study. Updated data was presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. A total of 127 patients were infused with obe-cel. By the data cut-off on September 13, 2023,

  • 74% of patients with morphological disease (n = 98) achieved a complete remission/complete response with incomplete count recovery rate;
  • 95% of responders were measurable residual disease-negative;
  • high complete response/complete response with incomplete count recovery rates were seen across all subgroups, including those with high-burden and extramedullary disease;
  • the 12-month event-free survival rate was 50%; and
  • obe-cel demonstrated long-term persistence and a favorable safety profile, with low rates of Grade ≥3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome reported.2

For this indication, obe-cel previously received Orphan Drug Designation and Regenerative Medicine Advanced Therapy designation by the FDA, as well as Orphan Medical Product Designation and Priority Medicines designation by the European Medicines Agency (EMA).1

  1. Autolus. Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory adult B-cell acute lymphoblastic leukemia (ALL). Published January 22, 2024. Accessed January 24, 2024
  2. Roddie C. Obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult b-cell acute lymphoblastic leukemia (R/R B-ALL): Pooled analysis of the ongoing FELIX phase Ib/II study. Oral abstract #222. 65th American Society of Hematology Annual Meeting and Exposition; Dec 9, 2023; San Diego, US.


Subscribe to get the best content related to ALL delivered to your inbox